Daniel Medeiros Lobo1, Aline Cristina Tritto2, Luana Rodrigues da Silva1, Paloma Borges de Oliveira1, Fabiana Braga Benatti1, Hamilton Roschel3, Barbara Nieß4, Bruno Gualano5, Rosa Maria Rodrigues Pereira1. 1. Bone Laboratory Metabolism, Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Brazil. 2. School of Physical Education and Sport, Universidade de São Paulo, Brazil. 3. Bone Laboratory Metabolism, Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Brazil; School of Physical Education and Sport, Universidade de São Paulo, Brazil. 4. AlzChem AG, Germany. 5. Bone Laboratory Metabolism, Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Brazil; School of Physical Education and Sport, Universidade de São Paulo, Brazil. Electronic address: gualano@usp.br.
Abstract
OBJECTIVE: We aimed to investigate the effects of a one-year low-dose creatine supplementation trial on bone health, lean mass, and muscle function in older postmenopausal women. METHODS: A double-blind, randomized, parallel-group, placebo controlled trial was conducted between November 2011 and November 2013 in Sao Paulo, Brazil. Postmenopausal osteopenic women were randomly allocated (1:1) into creatine (n=56; 1g/d) or placebo group (n=53; dextrose at same dose). At baseline and after one year of intervention, we assessed parameters of bone health, body composition, and muscle function. Blood parameters were also assessed before and after the intervention and adverse events were recorded throughout the trial. Possible differences in dietary intake were assessed by three 24-h dietary recalls. RESULTS:Bone mineral density at lumbar spine, femoral neck, total femur, and whole body did not differ within- or between-groups. No significant changes in body weight, BMI, absolute and relative body fat, and body lean mass were observed. Muscle function, as assessed by timed-up-and-go and timed-stands tests, were not significantly changed within- or between-groups. Safety laboratory parameters remained unaltered. CONCLUSION: A one-year low-dose creatine supplementation (1g/d) was free of adverse effects, but did not affect bone health parameters, lean mass, or muscle function in older women. Further studies with longer follow-up periods and higher doses of creatine supplementation are warranted. (Registered at clinicaltrials.gov as NCT01472393).
RCT Entities:
OBJECTIVE: We aimed to investigate the effects of a one-year low-dose creatine supplementation trial on bone health, lean mass, and muscle function in older postmenopausal women. METHODS: A double-blind, randomized, parallel-group, placebo controlled trial was conducted between November 2011 and November 2013 in Sao Paulo, Brazil. Postmenopausal osteopenicwomen were randomly allocated (1:1) into creatine (n=56; 1g/d) or placebo group (n=53; dextrose at same dose). At baseline and after one year of intervention, we assessed parameters of bone health, body composition, and muscle function. Blood parameters were also assessed before and after the intervention and adverse events were recorded throughout the trial. Possible differences in dietary intake were assessed by three 24-h dietary recalls. RESULTS: Bone mineral density at lumbar spine, femoral neck, total femur, and whole body did not differ within- or between-groups. No significant changes in body weight, BMI, absolute and relative body fat, and body lean mass were observed. Muscle function, as assessed by timed-up-and-go and timed-stands tests, were not significantly changed within- or between-groups. Safety laboratory parameters remained unaltered. CONCLUSION: A one-year low-dose creatine supplementation (1g/d) was free of adverse effects, but did not affect bone health parameters, lean mass, or muscle function in older women. Further studies with longer follow-up periods and higher doses of creatine supplementation are warranted. (Registered at clinicaltrials.gov as NCT01472393).
Authors: Deborah L de Guingand; Kirsten R Palmer; Rodney J Snow; Miranda L Davies-Tuck; Stacey J Ellery Journal: Nutrients Date: 2020-06-15 Impact factor: 5.717
Authors: Ciaran M Fairman; Krissy L Kendall; Robert U Newton; Nicolas H Hart; Dennis R Taaffe; Raphael Chee; Colin I Tang; Daniel A Galvão Journal: BMJ Open Date: 2019-09-20 Impact factor: 2.692